| Author and year of publication | Country | Study design | Follow-up (in days) | Study subjects | Sample size | Male % | Included age groups |
| Mwaiswel, 2016 | Tanzania | A randomized, single-blind clinical trial | 28 | 110 | 50 | >/=1 year | Koita, 2017 | Mali | A randomized, clinical trial | 42 | 33 | 100 | ≥18 years | Yeka, 2016 | Uganda | A randomized trial | 28 | 302 | 54 | 6 to 59 months | Ndounga, 2015 | Congo | A randomized study | 28 | 133 | 57.1 | <10 years | Ebstie, 2015 | Ethiopia | Observational cohort study | 28 | 130 | 60 | >5 years | Sirima, 2016 | Sub-Saharan Africa | A randomized, multicentre, trial | 63 | 407 | 49 | <5 years | Chandra, 2015 | Multi-center | A randomized, open-label study | 42 | 131 | 50.4 | 6 to 59 months | Kilonzi, 2019 | Tanzania | Prospective study | 28 | 100 | 56 | 6 to 59 months | Sondo, 2015 | Burkina Faso | A randomized open-label trial | 28 | 340 | 53.8 | All age | Salvador, 2017 | Mozambique | Prospective one-arm study | 28 | 349 | 52.3 | Children | Davlantes, 2018 | Angola | An in vivo assessment | 28 | 185 | 54 | Children | Kakolwa, 2018 | Tanzania | Open-label single arm study | 28 | 182 | 50 | >/=6 months | Plucinski, 2015 | Angola | Open-label, nonrandomized study | 28 | 157 | nr | 6 months to 9 years | Denoeud,2016 | Mali and Niger | Open comparative intervention study | 28 | 397 | 47.8 | < 5 years | Mekonnen, 2015 | Ethiopia | Open-label single arm study | 28 | 93 | 59.8 | >6 months | Plucinski, 2017 | Angola | Open-label single arm study | 28 | 178 | 60 | 6 months to 12 years | Smith, 2018 | Sierra- Leone | One-arm prospective study | 28 | 64 | 65.6 | 6 to 59 months | Ebenebe, 2018 | Nigeria | Open-label trial | 28 | 324 | 53.7 | <5 years | Warsame, 2017 | Somalia | One-arm prospective study | 28 | 284 | 66.9 | 6 months to 60 years | Grandesso,2018 | Niger | One-arm prospective study | 42 | 218 | 50 | 6 to 59 months | Adeel, 2016 | Sudan | One-arm prospective study | 28 | 595 | 48 | All age group | Niaré, 2016 | Mali | Randomized open-label assay | 28 | 237 | 58.7 | >/= 6 months | Paczkowski, 2016 | Malawi, | Randomized efficacy trial | 28 | 338 | 52.1 | 6 to 59 months | De Wit, 2016 | D.R. Congo | Open-randomized trial | 42 | 144 | 79 | 6 to 59 months | Dambe, 2015 | Malawi | One-arm prospective study | 28 | 322 | 49.6 | 6 to 59 months | Wudneh, 2016 | Ethiopia | Open-label trial | 28 | 91 | 82.4 | >/=6 months | Roth, 2018 | Kenya | A randomized controlled trial | 28 | 96 | 50 | 6 months to ≤12 years | Nji, 2015 | Cameroonian | Randomized trial | 42 | 142 | 47.2 | 6 months to 10 years | Ukah, 2015 | Nigeria | Double-blind randomized trial | 28 | 75 | 0 | Pregnant women | Dama, 2018 | Mali | Randomized trial | 42 | 158 | 53 | All age group | Sowunmi, 2017 | Nigeria | Randomized trial | 42 | 517 | 57 | </=15 years | Sowunmi, 2016 | Nigeria | Randomized trial | 28 | 517 | 55.1 | </=15 years | Nega, 2016 | Ethiopia | Open-label single-arm study | 28 | 91 | 75.8 | All age group | Teklemariam, 2017 | Ethiopia | Open-label single-arm study | 28 | 92 | 61.9 | All age group | Ogouyèm2016 | Benin | Open-label, single-arm trial | 42 | 123 | 63 | 6 months to 5 years | Getnet, 2015 | Ethiopia | One-arm prospective study | 28 | 80 | 57.5 | All age groups | Ayogu, 2015 | Nigeria | A prospective study | 28 | 154 | 22.7 | All age group | Abuaku, 2016 | Ghana | One-arm prospective study | 28 | 170 | 55 | 6 months to 9 years | Dorkenoo, 2016 | Togo | One-arm prospective study | 28 | 261 | 54.8 | 6 to 59 months |
|
|